BioWorld MedTech

May 22, 2018

FDA gives nod to Cerenovus for Embotrap II

Cerenovus, a unit of New Brunswick, N.J.-based Johnson & Johnson Corp. (J&J), received 510(k) clearance for the Embotrap II to capture and remove blood clots from the brain following an ischemic stroke. Read More

Micro-cap Dx player Precipio launches pancreatic liquid biopsy from Dana-Farber

Debate over stent vs. balloon for restenosis revived yet again

GE Healthcare's partnership with Singapore's A*STAR sees progress in imaging modalities

New funding helps Australia's med-tech industry push upward

Other news to note

Appointments and advancements

Product briefs

BioWorld MedTech's Cardiology Extra

Today's news in brief

BioWorld

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld

Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...

3D rendering of skin cells and elastin with collagen layer

First-in-class pan-inflammasome blocker for hidradenitis suppurativa

BioWorld Science

Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.

Illustration of cancer cell in crosshairs being destroyed

RX-10616 improves radiotherapy efficacy in HNSCC

BioWorld Science

Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...

CROI 2026: Neurodegeneration, the challenge of aging with HIV

BioWorld

Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...